Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 186Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 41Recurrence 28Neoplasms, Plasma Cell 27Lymphoma 25Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 20Lymphoma, B-Cell, Marginal Zone 15Lymphoma, Non-Hodgkin 14Leukemia, Myeloid, Acute 13Smoldering Multiple Myeloma 9Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 7Lymphoma, B-Cell 7Waldenstrom Macroglobulinemia 6Neoplasms 6Neoplasm, Residual 6Immunoglobulin Light-chain Amyloidosis 6Lymphoma, T-Cell 5Leukemia, Plasma Cell 5Leukemia, Myelomonocytic, Chronic 5Renal Insufficiency 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Hematologic Diseases 4Sezary Syndrome 3

Interventions

Carboplatin 3Radiotherapy 2Doxorubicin 2tipifarnib 1etoposide phosphate 1becatecarin 1Vincristine 1Temozolomide 1Tamoxifen 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1RMP 7 1Perfusion Magnetic Resonance Imaging 1Oxaliplatin 1Megestrol Acetate 1Lenalidomide 1Irinotecan 1Immunologic Techniques 1Etoposide 1Endostatins 1Dynamic Contrast Enhanced Magnetic Resonance Imaging 1Cyproheptadine 1Cisplatin 1Cilengitide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Optic Nerve Glioma × Lenalidomide × Clear all
NCT01553149 2025-01-07

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

National Cancer Institute (NCI)

Phase 2 Completed
75 enrolled 17 charts
CNS

Astrocytoma, Neurofibromatosis 1, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡